Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Oct 2000
Clinical TrialCYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
CYP2C19 has an important role in the catabolism of several proton pump inhibitors. However, the relative contribution of CYP2C19-mediated metabolism varies among the different proton pump inhibitors. ⋯ CYP2C19 genotype status influences gastric acid suppression by lansoprazole, but not by rabeprazole.